학술논문
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
Document Type
Article
Author
Bischoff, Philip; Reck, Martin; Overbeck, Tobias; Christopoulos, Petros; Rittmeyer, Achim; Lüders, Heike; Kollmeier, Jens; Kulhavy, Jonas; Kemper, Marcel; Reinmuth, Niels; Röper, Julia; Janning, Melanie; Sommer, Linna; Aguinarte, Lukas; Koch, Myriam; Wiesweg, Marcel; Wesseler, Claas; Waller, Cornelius F.; Kauffmann-Guerrero, Diego; Stenzinger, Albrecht
Source
Journal of Thoracic Oncology; May2024, Vol. 19 Issue 5, p803-817, 15p
Subject
Language
ISSN
15560864